1. Marginal zone lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance.
- Author
-
Lasica, Masa, Anderson, Mary A., Boussioutas, Alex, Gregory, Gareth P., Hamad, Nada, Manos, Kate, McKelvie, Penny, Ng, Michael, Campbell, Belinda, Palfreyman, Emma, Salvaris, Ross, Weinkove, Robert, Wight, Joel, Opat, Stephen, and Tam, Constantine
- Subjects
CONSENSUS (Social sciences) ,MEDICAL protocols ,NON-Hodgkin's lymphoma ,CANCER relapse ,TREATMENT effectiveness ,SYMPTOMS - Abstract
Marginal zone lymphomas (MZLs) are a rare, indolent group of non‐Hodgkin lymphomas with different diagnostic, genetic and clinical features and therapeutic implications. The most common is extranodal MZL of mucosa‐associated lymphoid tissue, followed by splenic MZL and nodal MZL. Patients with MZL generally have good outcomes with long survival rates but frequently have a relapsing/remitting course requiring several lines of therapy. The heterogeneous presentation and relapsing course present the clinician with several diagnostic and therapeutic challenges. This position statement presents evidence‐based recommendations in the setting of Australia and New Zealand. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF